Procedures designed to prevent microbiological contamination of diug products purpo1iing to be sterile did not include adequate validation of the aseptic process.
Inspection Record
Biocon Sdn. Bhd. — FDA 483 Findings
Inspectors Paranthaman Senthamarai KannanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
The batch production and conti·ol records are deficient in that they do not include documentation of the accomplishment ofeach significant step in manufacturing, processing, and packing.
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records are instituted by authorized personnel.
Procedmes designed to prevent microbiological contamination of diug products pmpo1iing to be sterile are not established, written or followed.
Aseptic processing areas ai·e deficient regai·ding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
There is a failure to review any unexplained discrepancy whether or not the batch has been ah-eady distributed.
The responsibilities and procedures applicable to the quality conti·ol unit are not in writing and folly followed.
About this record
Extracted automatically from the document US FDA published on 2025-06-20. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
